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IMMUNOBIOLOGY
SUMO conjugation of STAT1 protects cells from hyperresponsiveness to IFN
*Andreas Begitt,1 *Mathias Droescher,1 Klaus-Peter Knobeloch,2 and Uwe Vinkemeier1
1School of Biomedical Sciences, Nottingham University Medical School, Nottingham, United Kingdom; and 2Neuropathologie, Klinikum der
Albert-Ludwigs-Universita¨t, Freiburg, Germany
The biologic effects of IFN are mediated
by the transcription factor STAT1. The
activity of STAT1 is inhibited by small
ubiquitin-like modifier (SUMO) conjuga-
tion. This occurs both directly through
decreasing STAT1 tyrosine phosphoryla-
tion and indirectly by facilitating STAT1
dephosphorylation consequential to in-
creased STAT1 solubility because of sup-
pressed paracrystal assembly. However,
the physiologic implications of SUMO
conjugation have remained unclear. Here,
we used fibroblasts and bone marrow–
derived macrophages (BMMs) from knockin
mice expressing SUMO-free STAT1 to ex-
plore the consequences of STAT1 sumoyla-
tion for IFN signaling. Our experiments
demonstrated buffer property of paracrys-
tals for activated STAT1, such that SUMO-
mediated paracrystal dispersal profoundly
reduced phosphorylation of STAT1, which
affected both the activating tyrosine 701 and
the transcription-enhancing serine 727. Ac-
cordingly, the curtailed STAT1 activity in the
nucleus caused by SUMO conjugation re-
sulted in diminished transcription of IFN-
responsive genes; and increased the IFN
concentration more than 100-fold required
to trigger lipopolysaccharide-induced cyto-
toxicity in bone marrow–derived macro-
phages. These experiments identify SUMO
conjugation of STAT1 as a mechanism to
permanently attenuate the IFN sensitivity
of cells, which prevents hyperresponsive-
ness to this cytokine and its potentially
self-destructive consequences. This sets the
mode of SUMO-mediated inhibition apart
from the other negative STAT regulators
known to date. (Blood. 2011;118(4):
1002-1007)
Introduction
IFN fulfills multiple roles in immunity by regulating gene
expression.1 Its actions are largely dependent on STAT1 activation
by phosphorylation of tyrosine 701 as demonstrated by impaired
antimicrobial immunity of patients and model organisms with
defective STAT1 activation.2-6 Several additional posttranslational
modifications have been proposed to modulate the transcriptional
activity of STAT1,7 one modification of which is phosphorylation
of serine residue 727 in the transactivation domain,8,9 which is
required for full-fledged IFN-dependent innate immunity.10 In
contrast, whether posttranslational modifications of STAT1 contrib-
ute to its negative regulation is less clear. The proposed inhibition
of IFN signaling by acetylation of STAT1 on lysines 410 and
413 has recently been falsified,11 and the physiologic significance
of another covalent modification of STAT1, the conjugation of
small ubiquitin-like modifier (SUMO), has not been fully ex-
plored.12-15 STAT1 harbors a functional sumoylation consensus
sequence (KxE; , large hydrophobic residue; x, any residue)
with the SUMO acceptor Lys703 in position 2 relative to the
Tyr701 phosphorylation site.12 The SUMO consensus is evolution-
arily conserved in STAT1 but mutated in the other STAT family
members.15 SUMO modification is a dynamic and reversible
process with generally repressive effects on the transactivation of
transcription factors, but exceptions have been reported previ-
ously.16 We and others have recently shown that phosphorylation of
STAT1 at Tyr701 and sumoylation at the adjacent Lys703 are
mutually exclusive, such that transcriptionally active, that is,
Tyr701-phosphorylated STAT1, remains unsumoylated.17,18 This
phenomenon constitutes 1 of 2 mechanisms by which sumoylation
diminishes the pool of activated STAT1, that is, reducing Tyr701
phosphorylation at the cytokine receptors. It was further demon-
strated that activated STATs can polymerize into dynamic paracrys-
talline arrays in the nucleus of cytokine-stimulated cells and that
localization in paracrystals protects the activated STATs from
phosphatase attack.18 However, STAT1’s unique ability among the
STATs to SUMO conjugate triggers dimers that are semiphosphory-
lated at Tyr701, which dimers function as competitive polymeriza-
tion inhibitors and hence preclude paracrystal assembly. Thus,
sumoylation, although affecting only a disproportionately small
fraction of STAT1 molecules ( 2% at steady state), dramatically
increases the solubility of the activated STAT1. This, in turn,
constitutes the second SUMO-dependent mechanism to diminish
the activity of STAT1, that is, increased dephosphorylation. To-
gether, these 2 additive mechanisms profoundly curtail the pres-
ence of activated STAT1 in the cell nucleus.18 But, it was not
resolved how these consequences of STAT1 SUMO conjugation
affect IFN signaling. Here, we explore the impact for cellular
phenotype, and we report that SUMO conjugation of STAT1 raises
the threshold of IFN responsiveness essential to protect cells
against hyperresponsiveness to this cytokine.
Methods
Animal experimentation and cell culture
Mice expressing SUMO-free STAT1 (Glu705Gln) were generated using
knockin approach and maintained on a mixed 129/C57Bl/6 background
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(M.D., A.B., U.V., K.-P.K., and Ronald Naumann, manuscript in prepara-
tion). Embryonic fibroblasts were prepared from 13.5-day-old embryos by
standard methods and were genotyped by restriction fragment length
polymorphism analysis. Bone marrow from 17-week-old wild-type or
homozygous mutant mice was cultured in L cell–conditioned medium to
obtain macrophages,19 which were used for experiments between days 8
and 22. Culture of cell lines and transfections were described previously.20
NO assay and cell viability
NO production was assessed by nitrite determination using Griess assay;
cellular ATP content was measured with CellTiter-Glo assay to score
metabolic activity. Both assays were performed as described by the
manufacturer (Promega).
End point PCR and real-time PCR
Total RNA extraction and end point RT-PCR were done as described
previously.20 Real-time PCR was performed in a final volume of 25 L
containing 0.2 g of each primer and 0.5 g of template cDNA. Results for
real-time PCR were obtained using the QantiTect SYBR Green PCR kit
(QIAGEN) and the iCycler instrument (Bio-Rad Laboratories). The follow-
ing real-time PCR protocol was used: 2-minute denaturation at 95°C,
followed by 45 cycles of 95°C for 30 seconds, primer-specific annealing for
30 seconds and 72°C for 1 minute; the melting curve program was 55°C for
1 minute and 80 cycles of 55°C 0.5°C/cycle (10 seconds). For each gene,
the relative quantification of its expression in comparison with the reference
gene (Gapdh) was determined 3 times as described previously.21 The primer
sequences used in PCR assays are in supplemental Table 1 (available on the
Blood Web site; see the Supplemental Materials link at the top of the online
article).
Quantitative immunoblotting
Whole cell extraction, 7% and 10% SDS-PAGE, quantitative immunoblot-
ting, and membrane stripping were as described previously.18 Primary
antibody decoration was detected with IRdye800-conjugated secondary
immunoglobulin; signals were quantified using the Odyssey system (Li-Cor
Biosciences). Nickel-nitrilotriacetic acid (Ni-NTA; QIAGEN) chromatogra-
phy was done as described previously.18
Fluorescence microscopy
Microscopy was done using a TCP-SP2 confocal microscope (Leica)
equipped with automated shutter and motorized X, Y, and Z stack controller
together with a Q-Imaging charge-coupled device camera with 12-bit gray
scale resolution.18 For immunofluorescence experiments, we used poly-
clonal anti-Tyr701–phosphorylated STAT1-specifc first antibody (Cell
Signaling Technology), and Cy3-coupled anti–rabbit IgG secondary anti-
body (Stratech Scientific). Images were acquired with a 63 /1.4 oil Ph3
CS objective (Leica) using immersion oil (Leica). Fluorescence signal
intensities were obtained with LCS Lite 2.61 software (Leica).
Results and discussion
The structurally conservative SUMO consensus mutation
Glu705Gln has minimal SUMO-independent effects on STAT1
activity,18 yet suffices to preclude SUMO conjugation (Figure 1A).
To study the physiologic consequences, we therefore generated
STAT1-Glu705Gln knockin mice that exclusively express STAT1
from the endogenous gene locus and that can no longer be SUMO
conjugated. As shown in Figure 1B, primary fibroblasts (mouse
embryonic fibroblasts) extracted from embryos expressing SUMO-
free STAT1 did not present Tyr701-phosphorylated STAT1 irrespec-
tive of the genotype. On IFN stimulation, however, small STAT1
paracrystals containing Tyr701-phosphorylated STAT1 appeared in
the nucleus of cells expressing SUMO-free STAT1, which were
absent for activated wild-type STAT1. Comparison of Tyr701-
phosphorylation revealed increased and prolonged activation of the
mutant STAT1 (Figure 1B). In addition, mouse embryonic fibro-
blasts were treated with IFN for 60 minutes followed by a pulse
chase with the tyrosine kinase inhibitor staurosporine to block
continued Tyr701-phosphorylation.22 Immunoblotting revealed that
increased activation of SUMO-free STAT1 resulted not solely from
facilitated Tyr701-phosphorylation but also from markedly reduced
dephosphorylation (Figure 1B-C). These results were confirmed
and extended with primary BMMs, where SUMO-free STAT1
assembled very large paracrystals on IFN stimulation, whereas
wild-type STAT1 remained soluble (Figure 1D). Paracrystal incor-
poration protects activated STAT1 molecules from phosphatase
attack;18 however, thus far only Tyr701 modification has been
considered. We therefore examined modification at the second
confirmed STAT1 phosphorylation site, namely, Ser727 in the
transactivation domain, which is required for increased transcrip-
tion activation and innate immune responses.10 As shown in Figure
1D, phosphorylation of Ser727 like that of Tyr701 was markedly
increased and thus persisted longer in the paracrystal-containing
marrow-derived macrophages expressing SUMO-free STAT1. This
finding agrees with a protective role of paracrystals for phosphory-
lated STAT1 and provides another mechanistic explanation for
increased transcriptional activity of STAT1 in the nucleus.
These results confirmed earlier work demonstrating paracrys-
tals to function as reservoirs for the activated STATs. In conjunc-
tion with the dynamic exchange of paracrystal-incorporated STAT1
with the diffusible pool in the nucleoplasm,18 paracrystals thus
appeared to have buffer-property for activated STAT1 rather than
being static depots. To directly test this possibility, we used
quantitative confocal immunofluorescence microscopy to deter-
mine the impact of paracrystals on the IFN-induced concentration
change of Tyr701-phosphorylated STAT1 in the soluble phase, that
is, the nucleoplasm (Figure 1E). We show results obtained with
transfected human embryonic kidney (HEK293T) cells, which
express low endogenous STAT1, because the large-sized paracrys-
tals found in the nucleus of macrophages minimized the remaining
area suitable for optical analyses, which often precluded meaning-
ful measurements of soluble STAT1. In the nucleus of HEK293T
cells expressing wild-type STAT1, Tyr701-phosphorylation of
soluble STAT1 peaked between 1 and 4 hours after the addition of
IFN, whereas it reached approximately double that value already
after 30 minutes in nuclei containing SUMO-free STAT1. After this
time, which coincided with the appearance of paracrystals, the
nuclear concentration of diffusible Tyr701-phosphorylated STAT1
fell sharply in these cells to below wild-type level within 90 min-
utes, resulting in a much narrower activation peak (Figure 1E).
Importantly, over the following 16 hours, the concentration of
diffusible activated STAT1 remained constant, at  70% of the
wild-type maximum. Of note, this behavior required assembly of
paracrystals, because in their absence SUMO-free STAT1 re-
sembled the wild-type situation, in which the nuclear concentration
of activated STAT1 dwindled to background levels within
 10 hours (Figure 1D). These data demonstrated a buffer property
of paracrystals that profoundly altered the kinetics of STAT1
activation in the nucleus.
Next, we examined the consequences of prolonged STAT1
activity for the expression of IFN-regulated genes. Transcription
kinetics was determined with embryonic fibroblasts from wild-type
and mutant STAT1 knockin littermates using end point RT-PCR.
Figure 2A shows that expression of IFN-responsive genes was
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Figure 1. SUMO-mediated paracrystal dispersal curtails STAT1 activity in the nucleus. (A) Green fluorescent protein (GFP)–tagged wild-type STAT1 or mutant
Glu705Gln (SUMO) was coexpressed with Ubc9 (all lanes) and His-tagged SUMO1 (lanes 1, 2, 4, and 5) in HEK293T cells. Whole cell extracts were prepared in buffer
containing 120mM N-ethyl-maleimide (Sigma-Aldrich) and subjected to native affinity chromatography on Ni-NTA agarose (QIAGEN) to enrich His-tagged SUMO1 conjugates.
Shown are the results of a representative immunoblot analysis of cell extracts and bound Ni-NTA chromatography fraction using anti STAT1-specific antibody (C24; Santa Cruz
Biotechnology). (B) Left: Immunofluorescence confocal micrographs of unstimulated or 1-hour IFN-stimulated (50 U/mL mouse IFN; Calbiochem) mouse embryonic fibroblasts derived
from SUMO-free STAT1-Glu705Gln (SUMO) knockin mice or wild-type littermates using anti–Tyr701-phosphorylated STAT1 antibody. Nuclei were stained with Hoechst dye. Right:
immunoblot analyses of corresponding whole cell extracts depicting STAT1 activation kinetics. Cells were left untreated or were treated with IFN for 60 minutes, after which
time the medium was replaced by growth medium without or with 0.5M tyrosine kinase inhibitor staurosporine. The cells were incubated for the indicated times before cell
extraction and consecutive Western blotting on the same membrane using anti-Tyr701–phosphorylated STAT1-specific antibody (Cell Signaling Technology), anti-STAT1–specific
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selectively increased in fibroblasts from mice expressing SUMO-
free STAT1, namely, intercellular adhesion molecule-1 (Icam1) and
CXC chemokine ligand-9 (Cxcl9, or Mig). Other genes were not
responsive to IFN in fibroblasts (inducible nitric-oxide synthase,
Nos2; data not shown), or their expression was not affected by
SUMO modification of STAT1, namely, guanylate binding protein
1 (Gbp1); interferon regulatory protein 1 (Irf1); CXC chemokine
ligand-10, known also as Ip10; transporter 1 (Tap1); and Stat1. This
outcome was largely confirmed for human fibrosarcoma cells
stably reconstituted with wild-type or SUMO-free STAT1 (supple-
mental Figure 1). We then examined transcription in BMMs, which
are highly responsive to IFN. We tested expression of Cxcl9,
Gbp2, Icam1, and Nos2, and we found that their expression was
increased up to 5-fold if STAT1 was not SUMO modified (Figure
2B). Consistent with the curtailed nuclear STAT1 activation profile,
sumoylation diminished STAT1-dependent transcription not only
in magnitude but also profoundly shortened its duration. The most
potent increase in transcriptional activation associated with SUMO-
free STAT1 was seen for Nos2 when IFN treatment was combined
with lipopolysaccharide (LPS) administration, which is known to
synergistically induce Nos2.23 In wild-type macrophages, Nos2
expression reached a plateau between 6 and 24 h of IFN/LPS
treatment (Figure 2C). Macrophages from littermates expressing
SUMO-free STAT1, in stark contrast, showed elevated and rising
Nos2 transcription, which was  10-fold higher than wild type at
the end of the 24-hour observation period. We subsequently used
Western blotting to determine the corresponding protein expressing
of NOS2 enzyme in the macrophages (Figure 2D), which showed
moderately increased protein expression on treatment with IFN
alone but dramatically increased enzyme expression on LPS
costimulation, thus faithfully mirroring the gene expression data.
Given the influence of sumoylation on STAT1 activation and
IFN-induced gene expression, this posttranslational modification
thus resembles another inhibitor of STAT1 activation, namely,
suppressor of cytokine signaling 1, which too is required for the
timely attenuation of IFN signaling. However, suppressor of
cytokine signaling 1 inhibits STAT1 temporarily by an IFN-
induced feedback mechanism,24 whereas SUMO conjugation oc-
curs constitutively,12 and therefore could function like a rheostat
that permanently diminishes cellular responsiveness to IFN.
To assess whether this was the case, we researched the impact
on cytotoxicity of BMMs, namely IFN and STAT1-dependent
production of the enzymatic product of inducible NOS, that is,
nitric oxide, which is critical for innate immunity and the control of
infections.25 BMMs were exposed to IFN or bacterial molecular
pattern, that is, LPS, and nitrite accumulation in the culture
supernatant was determined, an established assay for NO produc-
tion.3 As reported, treatment of wild-type macrophages either with
IFN (50 U/mL) or LPS (1 ng/mL) did not cause detectable nitrite
release (Figure 2E left panel).23 In contrast, SUMO-free STAT1-
expressing macrophages showed robust NO production in response
not only to IFN (Figure 2E right panel) but also to LPS,
suggesting that lack of sumoylation renders STAT1 more sensitive
to autocrine activation by LPS-induced type I IFN.26 The IFN
hyperresponsiveness was strikingly confirmed by cotreatment with
increasing IFN and LPS (1 ng/mL). Already at the lowest IFN
concentration used (0.01 U/mL) a strong NO response was ob-
served, with macrophages expressing SUMO-free STAT1. Wild-
type macrophages, in contrast, remained unresponsive still at the
10 times higher dose of IFN (Figure 2C). Even when the dose was
elevated 100-fold (1 U/mL), their NO production remained consid-
erably lower. Indeed, mutant macrophages showed increased
cytotoxicity at all interferon concentrations tested, although NO
production seemed to reach saturation. Cellular ATP content was
determined subsequently (Figure 2F), which demonstrated that
viability of macrophage of both genotypes expectedly decreased in
a time and NO concentration-dependent manner.27 Thus, the
heightened NO production of BMMs expressing SUMO-free
STAT1 agreed well with their demonstrated increase in both gene
transcription and protein expression of inducible nitric oxide
synthase shown in Figure 2C and D, respectively.
In sum, these results establish SUMO conjugation as an
essential permanent negative regulator of STAT1. This posttransla-
tional modification stands out from the known STAT1 inhibitors,
tyrosine phosphatases, suppressor of cytokine signaling proteins,
and protein inhibitor of activated STAT (PIAS) proteins,28 which all
require activated, that is, Tyr701-phosphorylated STAT1. SUMO,
in contrast, targets exclusively the unphosphorylated STAT1.17,18
As a result, SUMO diminishes the basic IFN sensitivity of cells
and thus protects them against hyperresponsiveness to this cytokine
with potent proinflammatory effects. This fundamental difference
to the other STAT1 inhibitors, namely, permanent desensitization of
STAT1 to IFN, however, seems at odds with the suggested need
for macrophage sensitization to low concentrations of IFN during
the early stages of immune responses.29 Future work will have to
revisit this question. The PIAS proteins, another group of negative
STAT1 regulators, can act as SUMO E3 ligases, but it has not been
established whether this activity contributes to their STAT1 inhibi-
tion.28,30 Our results rather support the view that it does not.12,31
This is concluded from the largely nonoverlapping effects that
PIAS proteins and SUMO have on STAT1. Aside from the fact that
SUMO conjugates to unphosphorylated STAT1 and PIAS proteins
associate with the phosphorylated STAT1,32 we note that SUMO-
mediated STAT1 inhibition entails diminished tyrosine and serine
phosphorylation. PIAS-mediated repression of STAT1-dependent
gene activation, in contrast, does not seem to be associated with
reduced STAT1 phosphorylation, because STAT1 phosphorylation
is not increased in cells lacking PIAS133 or PIAS4,34 or in cells
Figure 1. (continued) antibody (E23; Santa Cruz Biotechnology) and then anti–	-actin specific antibody (Sigma-Aldrich). Note that antibody E23 recognizes both STAT1
splice variants, full-length STAT1
, and truncated STAT1	. (C) Diagram depicting specific Tyr701-phosphorylation of SUMO-free and wild-type STAT1 using fibroblast extracts
as shown in panel B. IFN-stimulated wild type was set as 100. Data are presented as the mean SD of 3 independent immunoblot analyses for each STAT1 variant. (D) Left:
Immunofluorescence confocal micrographs of unstimulated or 1-hour IFN-stimulated (50 U/mL mouse IFN) BMMs from SUMO-free STAT1 (SUMO) knockin mice or
wild-type littermates using anti Tyr701-phosphorylated STAT1-specific antibody. Cell dimensions are shown using bright-field microscopy. Right: Representative immunoblot
analyses of corresponding whole cell extracts depicting STAT1 phosphorylation kinetics at residues Ser727 and Tyr701. Anti-Ser727–phosphorylated STAT1-specific antibody
(44-382G; Invitrogen), anti-Tyr701–phosphorylated STAT1-specific antibody (Cell Signaling Technology), and then anti-STAT1–specific antibody (M23; Santa Cruz
Biotechnology; note that this antibody recognizes full-length STAT1
 splice variant only) were used. (E) Time course of soluble activated STAT1 in the nucleus of HEK293T
cells expressing wild-type or SUMO-free STAT1, as determined by quantitative immunofluorescence confocal microscopy. Top left: Representative immunofluorescence
micrographs of cells before and after treatment with 5 ng/mL human IFN (Calbiochem) using anti-Tyr701–phosphorylated STAT1-specific antibody. Bottom: Scatter plot
depicting unprocessed fluorescence signal intensities recorded outside paracrystals and nucleoli in the nucleoplasm of 170-250 randomly selected cells per time point for each
STAT1 variant. For SUMO-free STAT1, cells with paracrystals and without are grouped separately; horizontal bars indicate average fluorescence signal intensity. Top right: Graph
depicting the time course of average fluorescence signal intensities. Data were background subtracted; in addition, to correct for the 15% of cells that were unresponsive to IFN (not
applicable to dataset SUMO with paracrystals), the bottom 15% intensities of each time point were excluded in this representation. Data are shown relative to the wild-type
maximum (t  2 h), which was set as 100.
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after removal of one allele of Pias4 or Pias1 in the Pias1/ or
Pias4/ background, respectively.35 In addition, as demonstrated
here, SUMO deficiency of STAT1 resulted in strongly increased
macrophage cytotoxicity, whereas similar effects are not associated
with PIAS1 and PIAS4 deficiencies,34,35 suggesting that PIAS
proteins do not participate in STAT1 sumoylation in vivo. Nonethe-
less, results obtained with PIAS-deficient cells demonstrate coop-
erativity between the different PIAS proteins, so that at present a
role for PIAS proteins in the augmentation of STAT1 sumoylation
cannot be ruled out. However, irrespective of the actual SUMO E3
Figure 2. Sumoylation of STAT1 desensitizes
cells to IFN. (A) End point RT-PCR analyses of
IFN-induced genes in mouse embryonic fibroblasts
derived from SUMO-free STAT1 (SUMO) knockin
mice or wild-type littermates. Cells were left un-
treated or treated with 50 U/mL mouse IFN for the
indicated times, followed by RNA extraction, reverse
transcription, and PCR. Shown are the Gapdh-
normalized signal intensities of ethidium bromide–
stained PCR products. Data are the mean and SEM
of 3 independent experiments. (B) Real-time PCR
analyses using BMMs from mice expressing SUMO-
free STAT1 (SUMO) or wild-type littermates. Cells
were left untreated or were treated with mouse IFN
(50 U/mL) for 6 or 24 hours. Shown are Gapdh-
normalized gene expression data (mean  SEM) of
3 independent experiments. (C) As in panel B, but
BMMs were left untreated or were cotreated with
IFN (50 U/mL) and LPS (1 ng/mL) for 3, 6, or
24 hours. Shown is the Gapdh-normalized expres-
sion of Nos2; values are mean SEM of 3 indepen-
dent experiments. (D) Consecutive immunoblot
analysis using NOS2-specific antibody (iNOS; BD
Biosciences) and then 	-actin antibodies with whole
cell extracts from macrophages derived from SUMO-
free STAT1 (SUMO) knockin mice or wild-type
littermates. The cells were treated for the indicated
times with IFN alone or in combination with LPS.
Data are representative of 2 independent experi-
ments. (E) Nitric oxide production of BMMS derived
from wild-type (left) or SUMO-free STAT1 knockin
mice (SUMO; right). Macrophages were seeded in
96-well plates at a density of 1  104 cells/well and
kept for 60 hours in L cell–conditioned medium (10%
L cell–supplemented DMEM with 10% calf serum)
supplemented for the indicated times with IFN or
LPS or combinations thereof. Half the culture super-
natant (50 L) and Griess reagent were subse-
quently used to determine absorption at 550 nm,
before nitrite concentrations were calculated using
a standard curve. Data are representative for
2 independent experiments carried out in duplicate.
(F) Corresponding viability of the cells used in panel
E, as determined by their ATP content. The value
obtained for cells kept in L cell–conditioned medium
for 60 hours was set to 100 and used as the
reference point.
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ligase activity responsible for STAT1 modification, SUMO-
mediated STAT1 inhibition is distinguished by its exquisite target
specificity, encoded in the defined single conjugation site on
STAT1.12,18 In conjunction with its great significance for IFN
signaling demonstrated here, the modulation of STAT1 SUMO
conjugation thus becomes feasible for pharmacologic interventions
with therapeutic potential in inflammatory and immune disorders.
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